JPMorgan ups Edgewise target, adds to Analyst Focus List

JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $45 from $34 and keeps an Overweight rating on the shares. JPMorgan also added Edgewise to its Analyst Focus List as a growth idea. The firm remains positive on the shares in anticipation of a number of catalysts across the pipeline, particularly renewed interest in EDG-7500. The full 12 week data in Q2 will be meaningful for the fundamental view on EDG-7500, the analyst tells investors in a research note. JPMorgan increasingly likes the setup for Edgewise in 2026.